Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 83Neoplasm Metastasis 9Prostatic Neoplasms, Castration-Resistant 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Castration-resistant Prostate Cancer 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic Disease × abiraterone × Genitourinary × Clear all
NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
192 enrolled
Genitourinary

Prostate Cancer Metastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡